Biotech Equities Are Finally Making Up Lost Ground
Insights - The biotech sector has taken a meaningful step towards making up lost ground. After consolidating between $290 and $320 for the last month, the NASDAQ … Continue Reading
Read NowInsights
Vertex Steps Into Gene Editing With CRISPR Tx Collab
Insights - All eyes were on Valeant Pharmaceuticals (VRX) Monday morning, but another ‘V’ name deserves credit for enabling some real science. Vertex Pharmaceuticals (VRTX) on Monday climbed aboard the gene editing bandwagon … Continue Reading
Read NowWell, That Was a Wild Week
Insights - Depending how you were positioned, this last week was one of the most entertaining, educational, and wild of the year. And the sell the news phenomenon … Continue Reading
Read NowIt Takes an Iron Stomach to Invest in Biotech Stocks
Insights - That was apparent yet again this week, with a slew of binary events that moved stocks in unexpected ways. Beginning with Zafgen (ZFGN). The developer … Continue Reading
Read Now
Neurocrine Chalks Up a Win With Latest Clinical Trial
Insights - Teva Pharmaceuticals (TEVA) purchased Auspex Pharmaceuticals this spring for $3.5 billion, primarily for access to the developmental SD-809 (deutetrabenazine), which was in mid-stage studies for the treatment of chorea associated with Huntington’s disease, tardive dyskinesia, and Tourette syndrome. But the larger pharma company has a competitor nipping at its heels.
Read NowBiotech Had a Compelling, Late-Week Rally
Insights - The iShares NASDAQ Biotech ETF (IBB) posted a major reversal from lows this Monday to close the week slightly in the green. That rally, most … Continue Reading
Read Now
Let’s List All of the Events Impacting Sentiment for Equities…
Insights - The NASDAQ Biotech Index (NBI) ended the week on a low note – just 2 percentage points from giving back the entirety of its gains … Continue Reading
Read Now